Oliver Dorigo

9PUBLICATIONS
73CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 21, 2026
Targeting CD24 activates macrophages to reduce tumor burden in preclinical models of solid tumors.

|Dec 11, 2025
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.

Robert L Hollis, Austin Miller, Heather A Lankes

|May 01, 2023
Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial.

Oliver Dorigo, Amit M Oza, Tanja Pejovic

|Nov 16, 2022
Monocytes: A Promising New TRAIL in Ovarian Cancer Cell Therapy.

Stephanie Chow, Oliver Dorigo

|Jun 24, 2022
Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer.

Kalika Kamat, Venkatesh Krishnan, Oliver Dorigo

|Jun 20, 2022
Revealing the human mucinome.

Stacy A Malaker, Nicholas M Riley, D Judy Shon

Pageof 2

Frequent Collaborators

2 joint publications

Stacy A Malaker

2 joint publications

Kayvon Pedram

2 joint publications

Carolyn R Bertozzi

2 joint publications

Diane Provencher